Analytics

With each year nonpharmaceuticals range of pharmacies in Russia is expanding. On the one hand, it may be explained by market logic, as namely parapharmaceutical goods, with are not accompanied by a limited margin, allow pharmacies to earn more. On the other hand, namely cosmetics with continuously expanding product line can improve…

The U.S. share of global drug spending is expected to decline from 41 percent in 2006 to 31 percent by 2016, primarily due to patent expiries and slower brand growth. In the U.S. and led by Lipitor, $103 billion (44%) of 2011 brand spending will shift to generics with substantially lower prices. Major U.S. brand products, including…

Drugs going off-patent in 2014 contribute just under $50 billion in pharmaceutical industry revenue. Not all products losing protection face imminent competition from generics; biological products and drugs delivered by devices are best poised to extend their money-spinning streak.

ТОР10 Rx drug launches in the out-of-pocket segment of Russia’s pharma market by sales, 2013

ТОР10 OTC drug launches in the out-of-pocket segment of Russia’s pharma market by sales, 2013*